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Abstract
Background: Previous studies have shown that infection with human immunodeficiency virus type
1 (HIV-1) causes acceleration of the synthesis of glutamine tRNA (tRNAGln) in infected cells. To
investigate whether this might influence HIV-1 to utilize tRNAGln as a primer for initiation of
reverse transcription, we have constructed HIV-1 proviral genomes in which the PBS and the A-
loop region upstream of the PBS have been made complementary to either the anticodon region
of tRNAGln,1 or tRNAGln,3 and 3' terminal 18 nucleotides of each isoacceptor of tRNAGln.
Results: Viruses in which the PBS was altered to be complementary to tRNAGln,1 or tRNAGln,3 with
or without the A-loop all exhibited a lower infectivity than the wild type virus. Viruses with only
the PBS complementary to tRNAGln,1 or tRNAGln,3 reverted to wild type following culture in SupT1
cells. Surprisingly, viruses in which the PBS and A-loop were complementary to tRNAGln,1 did not
grow in SupT1 cells, while viruses in which the PBS and A-loop were made complementary to
tRNAGln,3 grew slowly in SupT1 cells. Analysis of the PBS of this virus revealed that it had reverted
to select tRNAThr as the primer, which shares complementarity in 15 of 18 nucleotides with the
PBS complementary to tRNAGln,3.
Conclusion: The results of these studies support the concept that the HIV-1 has preferred tRNAs
that can be selected as primers for replication.
Background
HIV-1 reverse transcription is initiated with the extension
of the cellular tRNA that is bound to a specific sequence
on the viral RNA genome known as the primer-binding
site (PBS) [1-3]. The PBS is an 18-nucleotide sequence
located near the 5' end of viral RNA that is complementary
to the 3' terminal nucleotides of the primer tRNA used for
initiation [3]. HIV-1 specifically selects tRNALys,3 from the
intracellular milieu to be used as the primer for initiation
of reverse transcription [4,5]. The mechanism of how
HIV-1 specifically selects tRNALys,3 from the intracellular
milieu is not completely understood. Previous studies
have established that tRNALys,3 as well as tRNALys1,2 are
enriched in HIV-1 virions [6-8]. The Gag-Pol polyprotein
of HIV-1 is responsible, in part, for this enrichment of
tRNALys1,2,3 into the virions [4,6,8]. Studies have also dem-
onstrated that lysl tRNA synthetase can specifically inter-
act with HIV-1 Gag to facilitate incorporation of
tRNALys1,2,3 into HIV-1 virions [9-11]. Once this complex
is incorporated into virions though, it is not clear how and
why tRNALys,3 is specifically utilized as the primer for ini-
tiation of reverse transcription.
Published: 26 September 2006
Virology Journal 2006, 3:80 doi:10.1186/1743-422X-3-80
Received: 19 September 2006
Accepted: 26 September 2006
This article is available from: http://www.virologyj.com/content/3/1/80
© 2006 Li et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Virology Journal 2006, 3:80 http://www.virologyj.com/content/3/1/80
Page 2 of 7
(page number not for citation purposes)
Previous studies from our lab and others have taken a
genetic approach to understanding elements of HIV-1
primer selection [12-14]. For these studies, we have
mutated the PBS to be complementary to tRNAs other
than tRNALys,3. In general, mutation of the PBS to be com-
plementary to other tRNAs, including tRNALys1,2, results
in a virus that can transiently utilize the specific tRNA but
most of the time reverts back to rapidly utilize tRNALys,3
following in vitro culture [12-14]. Stabilization of alterna-
tive tRNAs use has been accomplished through additional
mutations upstream in the U5 region designated as the A-
loop, which is complementary to the anticodon region of
tRNALys,3 [15-19]. For some, but not all tRNAs, mutation
of the A-loop region as well as the PBS to be complemen-
tary to the anticodon and 3' terminal nucleotides, respec-
tively, of the tRNA allows this tRNA to be stably utilized
by HIV-1 as a primer for reverse transcription. Using this
strategy, we have generated viruses which stably utilized
tRNALys1,2, tRNAMet, tRNAHis, and tRNAGlu  [15-19]. A
recent study has also found that HIV-1 can be forced to
use tRNALys1,2 if mutations are made complementary to
nucleotides in the TϕC loop of tRNALys1,2 in a second
region upstream of the PBS, called the primer activation
site [20].
All viruses that utilize alternative tRNAs do not replicate as
efficiently as the wild type virus that utilizes tRNALys,3.
This result has lead to the speculation that the availability
of tRNA for primer selection might not be the same for all
tRNAs. To test this it will be necessary to alter the levels of
individual tRNA isoacceptors in cells. However, it is diffi-
cult to modulate the levels of tRNA in mammalian cells
without leading to toxicity. Previous studies by Kuchino et
al. though have found that the levels of a natural
glutamine suppressor tRNA which exists as a minor spe-
cies of glutamine tRNA (tRNAGln,3) in normal cells is
increased in murine leukemia virus (MuLV) infected cells
[21,22]. In follow up studies, Muller et al. found that
although the amount of the suppressor tRNAGln,3 was only
6% of the major glutamine tRNAGln,1 levels the amount of
suppressor increased almost 20 fold while the levels of
non-suppressor tRNAGln,1  remained the same in cells
infected with MuLV or HIV-1 [23,24]. Since the levels of a
particular tRNA (tRNAGln,3) increase following infection
with HIV-1, it might be possible to force HIV-1 to use this
isoacceptor of tRNAGln as a primer for replication. To test
this, we created viruses in which the PBS is complemen-
tary to the minor and major species of tRNAGln. We also
constructed viruses which contain additional mutations
in the A-loop regions to determine if this will affect the
stable use of these tRNAs as primers for HIV-1 reverse
transcription. Results of our study show that these viruses
with the PBS complementary to either tRNAGln species
were unstable and rapidly reverted back to utilize tRNA-
Lys,3. Inclusion of the A-loop complementary to the antico-
don of tRNAGln,3 resulted in a virus that did not revert to
utilize tRNALys,3 but selected an unexpected tRNA, tRNA-
Thr. The results of these studies suggest that certain tRNAs
are favored by HIV-1 for the selection as a primer for ini-
tiation of reverse transcription.
Results
Construction of HIV-1 proviral genomes with PBS and A-
loop complementary to tRNAGln
To determine if HIV-1 can utilize tRNAGln as a primer for
reverse transcription, we mutated the PBS to be comple-
mentary to a 3' terminal nucleotide of tRNAGln. The major
isoacceptor for tRNAGln  (tRNAGln,1) has an anticodon
CUG. A second tRNAGln has an anticodon UUG and is
referred to as the minor tRNAGln or tRNAGln,3 [21,22] (Fig-
ure 1A). Previous studies have shown that in HIV-1
infected cells, the levels of tRNAGln,3 are increased 20 fold
over that of uninfected cells [23]. The 3' terminal nucle-
otides of tRNAGln,1 and tRNAGln,3 differ only by a single
nucleotide (Figure 1B). We have also constructed two
additional proviruses in which the A-loop region of HIV-
1 was mutated to correspond to the anticodon sequences
of tRNAGln,1 and tRNAGln,3, respectively (Figure 1B).
Characterization of mutant HIV-1
The first step in the characterization of HIV-1 with the
PBSs alone or PBSs in combination with A-loop modifica-
tions to be complementary to tRNAGln was to determine
the effects on the infectivity of viruses following transfec-
tion. For these studies, we transfected the proviral
genomes into 293T cells and assayed the supernatants for
infectious virus using the JC53βL assay. We also deter-
mined the amounts of virus in the supernatants by using
a p24 antigen capture ELISA. The infectivity of the viruses
is represented as the amount of infectious units divided by
the p24 levels. Previous studies from our laboratory have
shown that for the most part, mutations within the PBS of
HIV genome results in viruses that exhibit infectivity
approximately 20% (or lower) of the wild type virus [25].
Similar results were found for viruses in which the PBS
was made complementary to tRNAGln,1 or tRNALys,3. No
significant differences were observed between viruses with
the PBS alone complementary to tRNAGln and viruses with
the PBS and A-loop complementary to tRNAGln. The virus
with a PBS and A-loop complementary to tRNAGln,1
though had the lowest infectivity, approximately 10% of
the wild type virus and half as much as the other viruses
in which the PBS was altered to be complementary to
tRNAGln,3 (data not shown).
We next analyzed the replication of these viruses in SupT1
cells. Infections were established with equal amounts of
infectious virus and replication was monitored by analysis
of p24 in the culture supernatant. The wild type virus
demonstrated a rapid increase in p24 antigen in the cul-Virology Journal 2006, 3:80 http://www.virologyj.com/content/3/1/80
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ture supernatant, peaking at approximately 14 days fol-
lowing initiation of the infection; the cultures for the wild
type virus were halted at day 28 post initiation of culture.
In contrast, viruses in which just the PBS alone was made
complementary to tRNAGln,1 or tRNAGln,3 exhibited slower
infection compared to the wild type. The p24 levels in the
culture supernatants increased slowly, reaching a maxi-
mum at days 35 to 49 post initiation of culture. The final
levels of p24 antigen detected in the culture supernatants
from these viruses were similar to those of the wild type
virus (Figure 2A). Viruses in which the PBS and A-loop
were made complementary to tRNAGln,1 or tRNAGln,3 had
considerably different replication profiles compared to
the viruses with mutations in the PBS alone. Viruses with
the PBS and A-loop complementary to tRNAGln,1 showed
no increase in p24 antigen culture over the period exam-
ined (56 days of in vitro culture), indicating that the virus
with this mutation in the PBS and A-loop did not undergo
detectable replication and re-infection. In contrast, viruses
with the PBS and A-loop complementary to tRNAGln,3 did
replicate and eventually demonstrated an increase in p24
antigen during the 56 day culture period (approximately
100 fold over the starting amount of virus (p24 antigen)
(Figure 2B).
We utilized PCR to amplify the U5-PBS region from inte-
grated proviruses found in cellular genomic DNA to iden-
tify the PBS of viruses following in vitro culture. We
analyzed cellular DNA obtained at day 42 from cultures
infected with viruses in which the PBS alone was mutated
to be complementary to tRNAGln,1 or tRNAGln,3 (Table I).
In both instances, we found that analysis of U5-PBS
obtained from viruses at 42 days post initiation of culture,
which corresponded to the time at which there was a rise
in p24 antigen, resulted in some of the viruses containing
PBS complementary to the starting tRNAGln. Surprisingly,
the major PBS recovered from analysis of both viruses was
complementary to tRNAThr, indicating both viruses had
switched their preference from tRNAGln to tRNAThr. By day
56, though, when both cultures had plateaued with the
p24 antigen and the cultured supernatant, we recovered
PBS that were complementary to tRNALys,3. Most proba-
bly, the process of reversion for this virus occurred
through the formation of the PBS complementary to
tRNAThr followed by the subsequent conversion to a PBS
complementary to tRNALys,3 which resulted in the high
level replication observed for both of these viruses. In con-
trast, analysis of viruses in which the U5-PBS was comple-
mentary to tRNAGln,3 gave a different pattern. In this case,
all of the PBS recovered were complementary to tRNAThr,
suggesting that the virus had selected tRNAThr from the
intracellular milieu rather than the starting tRNA(tRNA-
Gln,3) and was now stably using tRNAThr as the primer for
reverse transcription.
Discussion
The original intent of the experiments was to determine
whether HIV-1 would accept tRNAGln as a primer for initi-
ation of reverse transcription. Our experiments were
based on a previous study in which we found that MuLV
with a PBS mutated to be complementary to tRNAGln,1
grew well in tissue culture, even though MuLV prefers to
use tRNAPro as the primer for initiation of reverse tran-
scription [26]. In addition to the viruses with the PBS
complementary to tRNAGln,1, we also constructed viruses
in which the PBS was complementary to the minor spe-
tRNAGln and mutated proviral genomes Figure 1
tRNAGln and mutated proviral genomes. Panel A. Clo-
verleaf structure of tRNAGln,1 and tRNAGln,3. tRNAGln,1 
(major) and tRNAGln,3 (minor) are depicted. The tRNAs dif-
fer in the nucleotides within the PBS (boxed) as well as 
nucleotides in the anticodon region (boxed). The modified 
nucleotides are noted. The structures are taken from Kuch-
ino et al. [22]. Panel B. Modifications in the NL-4 proviral 
genome. NL-4 WT refers to the wild type NL-4 genome with 
the PBS and A-loop complementary to tRNALys,3. NL-4-Gln1 
refers to a modified proviral genome in which the PBS was 
modified to be complementary to the 3' terminal nucleotides 
of tRNAGln,1. NL-4 Gln1-AC also contains a PBS complemen-
tary to the 3' terminal nucleotides of tRNAGln,1 with addi-
tional modifications of the A-loop region (GAGTCAG) 
noted in bold. NL-4-Gln3 is an HIV-1 with the PBS modified 
to be complementary to the 3' terminal 18-nucleotides of 
tRNAGln,3. Note that the PBS is nearly identical with the 
exception of the T to C change in the PBS. NL-4 Gln3-AC 
refers to an HIV-1 in which the PBS was modified to be com-
plementary to tRNAGln,3 with additional modification in the 
A-loop region consisting of GAGTCAA which is complemen-
tary to the anticodon region of tRNAGln3.
A
C
U
C
C
C
A
A
G
G
U
G G CU C
A A
A
C G A G C C
U
ϕ U
A
G C
G
A
C
C
A
A
G U C
U
C
A
G
G
C U
C A C G
A D
G
G
DA A
G U G
D
A
GU
C
C
U
U
G
G
m1
ϕ
ϕ
ϕ
ϕ
m5 m5
m
m
m1
A
C
U
C
C
C
G
A
G
G
U
G G CU C
A A
A
C G A G C C
U
ϕ U
A
G C
G
A
C
C
A
A
G U U
U
C
A
G
G
C U
C A C G
A D
G
G
DA A
G U G
D
A
GU
C
C
C
U
G
G
m1
ϕ
ϕ
ϕ
ϕ
m5 m5
m
m
m1
m
tRNA
Gln1 Gln3
tRNA
GTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAAA
PBS A-loop
NL-4 WT
NL-4 Gln1 GTCAGTGTGGAAAATCTCTAGCAGTGGAGGTTCCACCGAGATTTGAAA
GTCAGTGGAGTCAGTCTCTAGCAGTGGAGGTTCCACCGAGATTTGAAA NL-4 Gln1-AC
GTCAGTGTGGAAAATCTCTAGCAGTGGAGGTCCCACCGAGATTTGAAA NL-4 Gln3
GTCAGTGGAGTCAATCTCTAGCAGTGGAGGTCCCACCGAGATTTGAAA NL-4 Gln3-AC
A
BVirology Journal 2006, 3:80 http://www.virologyj.com/content/3/1/80
Page 4 of 7
(page number not for citation purposes)
cies, tRNAGln,3. Since previous studies have shown that
this tRNA is induced in MuLV and HIV-1 infected cells at
levels approximately 20 fold over the basal level found in
cells [23]. Thus, we expected that HIV-1 might tolerate the
selection of tRNAGln as the primer for reverse transcrip-
tion. However, it was clear from our studies that viruses
with a PBS alone complementary to tRNAGln,1 or tRNAGln,3
were unstable and reverted back to use tRNALys,3. Thus,
even though expression of tRNAGln,3 might be enhanced
in HIV-1 infected cells, this tRNA is not a preferred tRNA
for selection.
Previous studies from our laboratory and others have
found that regions within U5 can be altered in such a way
as to facilitate the selection of alternative primers by HIV-
1 for reverse transcription [15-20]. A mutation of the
region upstream of the PBS (designated the A-loop) so as
to be complementary to the anticodon region of certain
tRNAs allows these tRNAs to be selected by HIV-1 as the
primer for reverse transcription. However, the inclusion of
regions within the A-loop that were complementary to
tRNAGln in combination with a PBS complementary to
tRNAGln had substantial effects on the stability and repli-
cation of these viruses. Viruses with a PBS and A-loop
complementary to tRNAGln,1 were essentially non-infec-
tious. While viruses in which only the PBS was altered to
be complementary to tRNAGln,1 (the major tRNAGln) were
infectious, they reverted back to utilize tRNALys,3 follow-
ing short-term in vitro culture. Interestingly, viruses in
which the PBS and A-loop were complementary to the
minor species of tRNAGln,3 were infectious albeit at a
greatly reduced level compared to the wild type virus.
Thus, forcing HIV-1 to use tRNAGln,1 or tRNAGln,3 severely
reduced the capacity for replication, indicating that this
particular tRNA was not available to the virus for primer
selection, even for low level of virus replication.
The surprising result of this study was the reversion of
viruses with the PBS complementary to tRNAGln to utilize
tRNAThr. How this selection occurred is not clear at this
time. Comparison of the PBS sequences between those
complementary to tRNAGln and tRNAThr revealed consid-
erable homology between the first nine nucleotides as
well as the last three nucleotides (Figure 3). Previous stud-
ies from our laboratory have shown that the first nine and
last three to five nucleotides can facilitate the reverse tran-
scription of HIV-1 in which the PBS was made comple-
mentary to alternative tRNAs [27]. It is clear that
following selection of tRNAThr the virus could, through
the process of reverse transcription, convert the PBS to be
complementary to this tRNA and allow limited growth.
Why the virus with a PBS and A-loop complementary to
tRNAGln,1 did not convert to use tRNAThr is unknown. It is
possible that the selection of tRNAThr is passive, rather
than active. Thus, if the virus happens to capture tRNAThr,
it will grow, albeit more slowly than the wild type virus.
The fact that the process of conversion goes through an
intermediate with a PBS complementary to tRNAThr sug-
gests this tRNA has a greater availability for capture than
Replication of HIV with PBS and A-loop complementary to  tRNAGln Figure 2
Replication of HIV with PBS and A-loop complemen-
tary to tRNAGln. Panel A. Replication of wild type and 
viruses with PBS complementary to tRNAGln,1. Infections 
were established in SupT1 cells with equal amounts of virus 
as determined by infectious units. p24 antigen was then 
assayed in the culture supernatants at weekly intervals fol-
lowing initiation of the experiment. Values for the wild type 
virus increased to greater than 104 nanograms/ml by approxi-
mately 14 days following initiation of the infection. The cul-
tures were terminated at day 28. Viruses derived from NL-4-
Gln1 and NL-4-Gln1-AC were carried out to approximately 
56 days post initiation of culture. Note that viruses derived 
from NL-4-Gln1-AC did not grow, as evidenced by p24 anti-
gen that were near the levels of mock infected cells. Cultures 
were terminated at day 56. Data is representative from three 
independent experiments. Panel B. Replication of viruses 
with the PBS complementary to tRNAGln,3. The replication of 
the wild type virus is depicted. Cultures initiated with viruses 
derived from NL-4-Gln3 and NL-4-Gln3-AC were moni-
tored over 56 days of culture. The viruses derived from NL-
4-Gln3 eventually reached levels approximating that of the 
wild type virus by day 42 through 56. Viruses derived from 
NL-4-Gln3-AC demonstrated a slow and gradual increase 
reaching levels approximately 1/100 of that of the wild type 
virus at the time of termination of the culture (day 56). Data 
is representative of three independent experiments.
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tRNAGln. Additional studies will be needed to address this
possibility.
Conclusion
In the current study, we have characterized the replication
of HIV-1 in which the PBS has been altered to be comple-
mentary to tRNAGln. Viruses were constructed in which
the PBS or PBS and A-loop were modified to be comple-
mentary to either tRNAGln,1 or tRNAGln,3. All viruses were
found to have poor replicative capacity and the PBS was
unstable following in vitro culture. However, analysis of
the PBS from integrated proviruses revealed that a new
tRNA, tRNAThr was preferred by HIV-1 for replication indi-
cating that HIV-1 prefers tRNAThr as a primer for replica-
tion.
The results of our study re-enforces the idea that HIV-1 has
preferences for the selection of certain tRNAs for replica-
tion. Obviously, the most preferred primer for selection is
tRNALys,3. However, the results from our current and pre-
vious studies indicate HIV-1 can tolerate other tRNAs as
primers. For example, in a previous study, we found that
viruses in which the PBS was mutated to be complemen-
tary to tRNATrp reverted to select tRNAMet as the primer for
reverse transcription [28]. Viruses such as those with a PBS
and A-loop complementary to tRNAHis and tRNALys1,2 and
tRNAGlu have been generated in our laboratory, suggesting
the these tRNAs also are acceptable for selection as prim-
ers [15-19,29]. Since HIV-1 can select other tRNAs as the
primer for reverse transcription, why HIV-1 does not use
these other tRNAs for replication is unknown. It is possi-
ble that HIV-1 could have access to several different tRNAs
during primer selection. However, under certain circum-
stances where tRNALys,3 is not favored, such as that with
proviral genomes with certain A-loop modifications, the
virus can select other tRNAs, such as tRNAMet and tRNAThr
as the primer for reverse transcription if sufficient comple-
mentarity with the PBS exists. Further understanding of
the process and what influences the preference for certain
tRNAs will be important to resolve the mechanism of
primer selection.
Materials and methods
Tissue culture
293T cells were grown in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum
(FBS), and SupT1 cells were grown in RPMI 1640 medium
supplemented with 15% FBS.
Construction of mutant proviral genomes
Mutagenesis was performed by using the QuikChange II
Site-Directed Mutagenesis Kit (Stratagene) according to
the manufacturer's instructions. The PBS sequence in the
shuttle vector pUC119PBS [29] was changed to be com-
plementary to the 18 3'-terminal nucleotides of tRNAGln3
using the primers 5'-
TGGAAAATCTCTAGCAGTGGAGGTCCCACCGAGATCT-
GAAAGCGAAAGGGAAACC-3' and 5'-
GGTTTCCCTTTCGCTTTCAGATCTCGGTGGGACCTC-
CACTGCTAGAGATTTT CCA-3', creating the plasmid
pUC-Gln3. pUC-Gln3 was then used as a template to
mutate the PBS to be complementary to tRNAGln1, with
the primers 5'-CTCTAGCAGTGGAGGTTCCAC CGA-
GATCTGAAAG-3' and 5'-CTTTCAGATCTCGGTGGAAC-
CTCCACTGCTAGAG-3', resulting in plasmid pUC-Gln1.
To create the plasmid pUC-Gln3AC, which contains fur-
ther mutations in the U5 region complementing the anti-
codon loop of tRNAGln3, PUC-Gln3 was used as a tem-
plate, along with the primers 5'-ACCTCCACTGCTAGA-
GATTGACTCCACTGACTA AAAGGGTCTGAGG-3' and 5'-
CCTCAGACCCTTTTAGTCAGTGGAGTCAATCTCTAGC
AGTGGAGGT-3'. Likewise, pUC-Gln1AC with U5
sequence complementary to the anti-codon loop of
tRNAGln1 was made by using PUC-Gln1 as a template,
with the primers 5'-CCTCAGACCCTTTTAGTCAGT-
GGAGTCAGTCTCTAGCAGTGGAGGT-3' and 5'-
Sequence complementarity of tRNAGln and tRNAThr with  mutant proviral genomes Figure 3
Sequence complementarity of tRNAGln and tRNAThr 
with mutant proviral genomes. Panel A. Sequence 
complementary of tRNAGln,3 with NL-4-Gln3-AC. Depicted 
is the predicted complementarity between the 3' terminal 
nucleotides and the PBS and the anticodon of tRNAGln,3 with 
the modified A-loop region of NL-4-Gln3-AC. Panel B. 
Complementarity between 3' terminal nucleotides of tRNA-
Thr with the PBS of NL4-Gln3-AC. Nucleotide differences 
within the PBS and tRNAThr are underlined. The anticodon 
region of tRNAThr has complementarity with the modified A-
loop region of NL-4-Gln3. Additional complementarity 
between tRNAThr and the PBS of NL-4-Gln1-AC is also 
shown. The single nucleotide difference between the PBS is 
underlined. The resulting GC pair of tRNAThr and the PBS of 
NL-4-Gln3-AC should be compensated for by a GU base 
pair. Note also the predicted complementarity between the 
anticodon region of tRNAThr with the modified A-loop region 
of NL-4-Gln1-AC.
ACCUCCAGGGUGGCUCUA
..GUCAA.........UGGAGGUCCCACCGAGAU..........
ACCUCCGGGGCGACCCUA
NL-4-Gln3-AC
GUU
tRNA
Gln3
..GUCAA.........TGGAGGUCCCACCGAGAU..........
AGU
tRNA
Thr
NL-4-Gln3-AC
A
B
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ACCTCCACTGCTAGAGACTGACTCCACTGACTAAAAG-
GGTCTGAGG-3'. Subsequently, the HpaI-BssHII frag-
ments of pUC-Gln3, pUC-Gln3AC, pUC-Gln1 and pUC-
Gln1AC containing the U5-PBS region were sub-cloned
between the SmaI and BssHII sites of pNL4-3 to form the
complete pro-viral clones of pNL4-3-Gln3, pNL4-3-
Gln3AC, pNL4-3-Gln1 and pNL4-3-Gln1AC. Sequences
of pro-viral clones were verified by DNA sequencing.
Transfection and analysis of viral infectivity
Plasmids were transfected into 293T cells using the
Fugene 6 Transfection Reagent (Roche Molecular Bio-
chemicals, Indianapolis, IN) according to the protocol.
Briefly, 2 µg of pro-viral plasmid DNA and 3 µl of Fugene
6 reagent were combined in 100 ul serum free DMEM,
and incubated at room temperature for 30 min. The mix-
ture was then added to one well of 6-well plate containing
60% confluent 293T cells in 2 ml fresh medium. The
transfections was incubated at 37°C overnight, before
replaced with fresh medium, and supernatants were col-
lected after 48 hours and stocked at -80°C in aliquots.
Levels of infectious virus (IU/µL) in 293T supernatants
were determined using the JC53βL assay as previously
described [25,30].
Infection and maintaining of viral cultures
Virus supernatant containing 250 infectious units were
added to 106 SupT1 cells in 125 µl RPMI supplemented
with 2% FBS in a 15 ml Falcon conical tube (BD Bio-
science) with caps loosened, and incubated at 37°C for 2
hrs to allow absorption, then transferred to a tissue culture
flask containing 10 ml RPMI supplemented with 15% FBS
to further culture the infected cells. Every 3–4 days, 8 ml
of culture were replaced with 8 ml fresh medium, and
supernatants and cell pellets were collected every 7 days
and stocked at -80°C. Once the infected SupT1 cultures
were found to be cleared of cells, 106 new SupT1 cells were
added to continue the culture.
DNA sequence analysis of pro-viral U5 and PBS region
High-molecular-weight DNA was isolated from SupT1 cell
pellets using the Wizard genomic DNA purification kit
(Promega, Madison, WI) according to the manufacturer's
instructions. A fragment containing the U5 and PBS
regions of the integrated provirus was PCR amplified from
the high-molecular weight DNA using primers 5'-
CGGAATTCTCTCCTTCTAGCCTCCGCTAGTC-3' and 5'-
CCTTGAGCAT GCGATCTACCACACACAAGGC-3'. The
PCR products were run on a 1% agarose gel and DNA run-
ning approximately 750 bp size were extracted using the
Qiagen Gel Purification Kit (Qiagen, Valencia, CA) and
sub-cloned into pGEM-T-Easy vector (Promega Madison,
WI) according to the protocol. White colonies were picked
and grown to produce DNA, which were screened for
inserts by EcoRI enzyme digestion. The U5-PBS sequence
of TA clones containing the approximately 750 bp inserts
were analyzed by automated DNA sequencing, using the
primer corresponding to the T7 promoter sequence flank-
ing the multiple cloning site of the vector.
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